IQVIA Q3 2026: Strongest Clinical Bookings Since 2022 Drive a Clean Beat
As seen on the 24/7 Wall St. homepage on October 27, 2026.
The CRO demand drought is over: net new clinical bookings of $3.2 billion marked the strongest clinical quarter since 2022. Management raised full-year adjusted EPS guidance to $12.90 to $13.00.
Continue ReadingShow less
IQVIA delivered a clean beat across every major line in the third quarter of 2026, with adjusted diluted EPS of $3.34 topping expectations and revenue growing year over year.
Net new clinical bookings of $3.2 billion in the Research and Development Solutions segment marked the strongest single clinical quarter for bookings since 2022, and the contracted R&DS backlog keeps building behind it.
Margin expansion came from higher win rates, a simplified organizational structure in place since January 2026, and the deployment of over 400 AI agents across clinical and commercial applications, with adjusted EBITDA reaching $1.03 billion.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
Management raised full-year 2026 adjusted diluted EPS guidance to a range of $12.90 to $13.00, and Bousbib pointed to favorable demand indicators including EBP funding, RFP flow, clinical trial starts, FDA approvals, and outsourcing trends as validation that the market environment continues to strengthen.
One item worth noting is a roughly $2.1 billion backlog adjustment tied to an inactive trial review, which partially offsets the otherwise strong bookings momentum. Investors will have another opportunity to hear from management at an Investor Day scheduled for December 1, 2026.
Mentioned: IQV